"Buy One Get One Free": Armed Viruses for the Treatment of Cancer Cells and their Microenvironment

被引:49
作者
Kaur, Balveen [1 ]
Cripe, Timothy P. [2 ,3 ]
Chiocca, E. Antonio
机构
[1] Ohio State Univ, Med Ctr, Dept Neurol Surg, James Comprehens Canc Ctr,Dardinger Lab Neuroonco, Columbus, OH 43210 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH USA
[3] Univ Cincinnati, Cincinnati, OH USA
关键词
Oncolytic viruses; tumor microenvironment; angiogenesis; extracellular matrix; cytokines; HERPES-SIMPLEX-VIRUS; ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; ADENOVIRUS EXPRESSING INTERLEUKIN-12; VESICULAR STOMATITIS-VIRUS; INHIBITS TUMOR-GROWTH; ONCOLYTIC ADENOVIRUS; ANTITUMOR-ACTIVITY; IN-VIVO; TISSUE INHIBITOR;
D O I
10.2174/156652309789753329
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Oncolytic viral therapy is a promising biological therapy for the treatment of cancer. Recent advances in genetic engineering have facilitated the construction of custom-built oncolytic viruses that can be exquisitely targeted to tumors by exploiting each cancer's unique biology and their efficacy can be further enhanced by "arming" them with additional therapeutic genes. Such an approach allows the virus to unload its "therapeutic cargo" at the tumor site, thereby enhancing its anti-neoplastic properties. While several clever strategies have been recently described using genes that can induce cellular apoptosis/suicide and/or facilitate tumor/virus imaging, viruses armed with genes that also affect the tumor microenvironment present an exciting and promising approach to therapy. In this review we discuss recently developed oncolytic viruses armed with genes encoding for angiostatic factors, inflammatory cytokines, or proteases that modulate the extracellular matrix to regulate tumor vascularization, anti-tumor immune responses and viral spread throughout the solid tumor.
引用
收藏
页码:341 / 355
页数:15
相关论文
共 153 条
[1]   Paths of FGFR-driven tumorigenesis [J].
Acevedo, Victor D. ;
Ittmann, Michael ;
Spencer, David M. .
CELL CYCLE, 2009, 8 (04) :580-588
[2]   Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide [J].
Aghi, Manish ;
Rabkin, Samuel D. ;
Martuza, Robert L. .
CANCER RESEARCH, 2007, 67 (02) :440-444
[3]   Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus [J].
Aghi, Manish K. ;
Liu, Ta-Chiang ;
Rabkin, Samuel ;
Martuza, Robert L. .
MOLECULAR THERAPY, 2009, 17 (01) :51-56
[4]   Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3 [J].
Ahonen, M ;
Ala-Aho, R ;
Baker, AH ;
George, SJ ;
Grénman, R ;
Saarialho-Kere, U ;
Kähäri, VM .
MOLECULAR THERAPY, 2002, 5 (06) :705-715
[5]   Pharmacologic and Chemical Adjuvants in Tumor Virotherapy [J].
Alvarez-Breckenridge, Christopher ;
Kaur, Balveen ;
Chiocca, E. Antonio .
CHEMICAL REVIEWS, 2009, 109 (07) :3125-3140
[6]   ADENOVIRUS EARLY REGION-1A MODULATION OF INTERFERON ANTIVIRAL ACTIVITY [J].
ANDERSON, KP ;
FENNIE, EH .
JOURNAL OF VIROLOGY, 1987, 61 (03) :787-795
[7]   Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins [J].
Andreansky, S ;
He, B ;
van Cott, J ;
McGhee, J ;
Markert, JM ;
Gillespie, GY ;
Roizman, B ;
Whitley, RJ .
GENE THERAPY, 1998, 5 (01) :121-130
[8]  
Aoki T, 2002, INT J ONCOL, V21, P629
[9]  
Auguste P, 2001, CANCER RES, V61, P1717
[10]   The impact of extracellular matrix on the chemoresistance of solid tumors -: experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy [J].
Baumgartner, G ;
Gomar-Höss, C ;
Sakr, L ;
Ulsperger, E ;
Wogritsch, C .
CANCER LETTERS, 1998, 131 (01) :85-99